Furthermore, DEK-AFF2 fusion, identified in head and neck cancer, was found to prime fusion-derived-neoantigen-specific cytotoxicity and revive efficacies of checkpoint inhibitors in tumors with low mutation burden and barren immune infiltration (Yang et al, 2019). The gene discussed is AFF2; the disease is head and neck cancer.